@zoomlik no dillution ”risk” anymore. They say fully funded to q1 2024 in investor presentation now. The offering was wise and expected. You need funding to expand the business and not be forced to give away your idea to big pharma. Now company is stronger. Dillution of shares is pretty much a dillusion, as the successful funding increases the value. Thus larger value now to divide among the shares. Price drop we just saw largely unmotivated the way I see it. If they had not been able to finance, and if institutions did not want shares at 20USD then that would have been scary.